<DOC>
	<DOCNO>NCT00562224</DOCNO>
	<brief_summary>To determine high dose study drug take without cause serious side effect patient advance cancer . The study look safety study drug whether treatment schedule tolerate patient .</brief_summary>
	<brief_title>Study Safety Tolerability Oral Capsule Form PCI-24781 Advanced Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Abexinostat</mesh_term>
	<criteria>age ≥ 18 year Histologically confirm , measurable solid tumor , nonHodgkin 's lymphoma , Hodgkin 's disease , chronic lymphocytic leukemia , multiple myeloma relapse standard therapy standard therapy exist Ability swallow oral capsule without difficulty Estimated life expectancy &gt; 12 week ECOG performance status ≤ 2 Creatinine ≤ 1.5 × institutional upper limit normal ( ULN ) Total bilirubin ≤ 1.5 × institutional ULN ( unless elevate document Gilbert 's syndrome ) AST ALT ≤ 2.5 × institutional ULN ( ≤ 5 × institutional ULN presence liver metastasis ) Platelet count ≥ 100,000/µL ANC ≥ 1500/µL Hgb ≥ 9.0 g/dL Patients previously treat , stable , asymptomatic brain metastasis corticosteroid eligible Willing able sign write informed consent Patients immunotherapy , chemotherapy , radiotherapy within 4 week ( within 6 week nitrosoureas mitomycin C ) prior first day drug dose Patients undergone major surgery within 4 week prior first day drug dose Patients receive another investigational drug within 4 week Evidence leptomeningeal metastasis Patients unable swallow oral medication preexist gastrointestinal disorder might interfere proper absorption oral drug ( eg , WDHA syndrome , carcinoid syndrome , diarrhea due infection , malabsorption syndrome secondary surgery chemotherapy ) Uncontrolled illness include limited : ongoing active infection , symptomatic congestive heart failure ( New York Heart Association Class III IV heart failure ) , unstable angina pectoris , cardiac arrhythmia , psychiatric illness would limit compliance study requirement Patients risk factor , receive medication know prolong QTc interval may associate Torsades de Pointes QTc prolongation ( define QTc interval ≥ 450 msec ) significant ECG abnormality include 2nd degree AV block type II , 3rd degree AV block , bradycardia ( ventricular rate le 50 beats/min ) . History myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty and/or stenting within past 6 month . Patients know HIV infection Pregnant lactate woman ( female patient childbearing potential must negative serum pregnancy test within 14 day first day drug dosing , , positive , pregnancy rule ultrasound )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>PCI-24781</keyword>
	<keyword>Neoplasms site</keyword>
	<keyword>Lymphoma , non-hodgkin</keyword>
	<keyword>Hodgkin disease</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Leukemia , lymphocytic , chronic</keyword>
</DOC>